Hyderabad: Patients of drug-resistant tuberculosis in the state will soon get a new regimen, which is expected to bring down the cost and also the time of treatment from 20 months to six. BPaLM regimen, a novel treatment method for Multi-DrugResistant Tuberculosis includes a new anti-TB drug called pretomanid, which has earlier been approved and licenced for use in India …
The Union health ministry has approved the shorter, less toxic, and more effective treatment regimen — BPaLM— against the multi-drug-resistant tuberculosis under its National TB Elimination Program. “While traditional MDR-TB treatments can last up to 20 months with severe side effects, BPaLM regimen can cure the drug-resistant TB in just six months with high treatment success rate,” the health ministry …
THIRUVANANTHAPURAM: Dr Vinay Nandicoori, director of CSIR-CCMB and a leading microbiologist, said that tuberculosis has remained as the number one killer among all infectious diseases, despite the clinical use of over 20 antibiotics and BCG, a century-old vaccine. Dr Nandicoori, a J C Bose Fellow, said that the gradual rise in the emergence of increasingly drug-resistant strains and HIV-TB co-infection …
Imagine buying a car worth ₹12 lakh and getting cashback worth two flight tickets to Singapore. After reaping the benefits, the 31-year-old recently guided his brother to buy a car using credit cards and earned about 6% worth of rewards. Funding a car purchase with credit cards is an attractive option because of the potential rewards it offers on the …